Publications

Members only publications are marked with a lock icon:
Filter By
Caring for the Ages
September 1, 2016
TORONTO — A phase III trial of an anti-tau drug has posted negative topline results, conferring no cognitive or functional benefits when given in conjunction with standard-of-care Alzheimer’s disease medications.
Caring for the Ages
September 1, 2016
Do any of your patients or the people you serve fit this profile?
Caring for the Ages
September 1, 2016
TORONTO — Researchers have described a behavioral syndrome that they say can be a forerunner of Alzheimer’s disease and other neurodegenerative diseases, and created a tool for diagnosing it.
Caring for the Ages
September 1, 2016
Delirium is one of the most difficult problems for hospitalists to manage, in part because our management of delirium is often learned on the fly during residency and early years of practice. This post-hoc approach toward delirium misses the most...
Caring for the Ages
September 1, 2016
The Foundation for Post-Acute and Long-Term Care Medicine (formerly the AMDA Foundation) Futures program has always been an amalgam of participants in various career stages from all across the country. A few years ago, the program began adding nurse...
Caring for the Ages
September 1, 2016
The Centers for Disease Control and Prevention is providing $67 million to help U.S. health departments address antibiotic resistance and related patient safety concerns.
Caring for the Ages
September 1, 2016
Dear Dr. Jeff:
Caring for the Ages
September 1, 2016
Renal function should be assessed in every nursing home resident, most importantly to ensure that medications will be prescribed appropriately, Milta Little, DO, CMD, said at the AMDA – the Society for Post-Acute and Long-Term Care Annual Conference...
Caring for the Ages
September 1, 2016
Despite achieving significant improvements in blood pressure and cholesterol levels, obese Americans continue to grow fatter, with worsening blood glucose and an increasing incidence of diabetes.
Caring for the Ages
September 1, 2016
TORONTO — Hallucinations — especially auditory hallucinations — triple the risk that a risperidone-controlled Alzheimer’s patient with psychoses will relapse if the drug is withdrawn.